Activation of NRF2 in myeloid-derived suppressor cells prevents metastasis and reverses tumor-mediated immune suppression [19;20;74]; therefore, a compound that activates NRF2 in the tumor microenvironment and directly inhibits tumor cell growth is a promising therapeutic approach. The gene discussed is NFE2L2; the disease is neoplasm.